Histogenics Corporation (HSGX) Stock Price, Forecast & Analysis

NASDAQ:HSGX

0.162
-0.07 (-30.77%)
At close: Sep 27, 2019
0.1589
0 (-1.91%)
After Hours: 9/27/2019, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

HSGX Key Statistics, Chart & Performance

Key Statistics
Market Cap15.33M
Revenue(TTM)N/A
Net Income(TTM)-2.68M
Shares94.60M
Float42.41M
52 Week High1.43
52 Week Low0.08
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-0.58
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
HSGX short term performance overview.The bars show the price performance of HSGX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40

HSGX long term performance overview.The bars show the price performance of HSGX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of HSGX is 0.162 null. In the past month the price decreased by -28.88%. In the past year, price decreased by -70.28%.

Histogenics Corporation / HSGX Daily stock chart

HSGX Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to HSGX. When comparing the yearly performance of all stocks, HSGX is a bad performer in the overall market: 93.2% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
HSGX Full Technical Analysis Report

HSGX Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to HSGX. HSGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
HSGX Full Fundamental Analysis Report

HSGX Financial Highlights

Over the last trailing twelve months HSGX reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 38.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -83.87%
ROE 30.74%
Debt/Equity -0.79
Chartmill High Growth Momentum
EPS Q2Q%88%
Sales Q2Q%N/A
EPS 1Y (TTM)38.3%
Revenue 1Y (TTM)N/A
HSGX financials

HSGX Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next Y96.2%
Revenue Next YearN/A
HSGX Analyst EstimatesHSGX Analyst Ratings

HSGX Ownership

Ownership
Inst Owners0.01%
Ins Owners7.79%
Short Float %N/A
Short RatioN/A
HSGX Ownership

About HSGX

Company Profile

Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts.

Company Info

Histogenics Corporation

830 WINTER STREET 3RD FLOOR

WALTHAM MA 02451

CEO: Adam Gridley

Phone: 781-547-7900

Histogenics Corporation / HSGX FAQ

What does Histogenics Corporation do?

Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts.


What is the stock price of Histogenics Corporation today?

The current stock price of HSGX is 0.162 null. The price decreased by -30.77% in the last trading session.


Does HSGX stock pay dividends?

HSGX does not pay a dividend.


What is the ChartMill technical and fundamental rating of HSGX stock?

HSGX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Which stock exchange lists HSGX stock?

HSGX stock is listed on the Nasdaq exchange.


What is the market capitalization of HSGX stock?

Histogenics Corporation (HSGX) has a market capitalization of 15.33M null. This makes HSGX a Nano Cap stock.